AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor International Website | For Healthcare Professionals Outside the U.S. | US Residents
Learn How to Start Your Patients on AFINITOR®
Starting patients with advanced renal cell carcinoma on AFINITOR (everolimus) tablets — and helping them stay with it — doesn’t have to be a challenge. Please explore the resources below for more information on helping your patients take their AFINITOR and understand what to expect throughout their treatment.
- Dosing & administration - Ease your patients' transition after initial VEGF**-targeted therapy — keep them on a daily oral therapy.
- Setting patient expectations - Find tips and information to help optimize patient starts, compliance and persistency.
- Patient support tools - Support resources for healthcare professionals to offer their patients with advanced renal cell carcinoma.
- Register for the AFINITOR Insights e-mail series - Sign up to receive timely and clinically relevant information about AFINITOR, advanced renal cell carcinoma and related health issues.
Next: Setting Patient Expectations
**VEGF: vascular endothelial growth factor
Disclaimer: This is an international website for AFINITOR® (everolimus) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
NovartisOncology.com |
About Novartis Oncology |
Contact Us |
Site Map
Use of website is governed by the Terms of Use and Privacy Policy
© 2010 Novartis AG